Tags : IGBA

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

WHO Signs MoU with IGBA for Promoting the Access to

Shots: The memorandum of understanding signed between WHO and International Generic and Biosimilar Medicines Association to facilitates the approval of generics and biosimilars thus reduces the burden of clinical trials for biosimilars and increases the access to drugs The WHO’s efforts to increase the access to Biosimilar includes List of International Comparators, providing information on […]Read More